CN101979657A - Method and kit for detecting rs2878677 locus of susceptibility gene of hypertension - Google Patents
Method and kit for detecting rs2878677 locus of susceptibility gene of hypertension Download PDFInfo
- Publication number
- CN101979657A CN101979657A CN 201010171050 CN201010171050A CN101979657A CN 101979657 A CN101979657 A CN 101979657A CN 201010171050 CN201010171050 CN 201010171050 CN 201010171050 A CN201010171050 A CN 201010171050A CN 101979657 A CN101979657 A CN 101979657A
- Authority
- CN
- China
- Prior art keywords
- gene
- hypertension
- site
- mfn2
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the field of molecular biology and medicine and relates to a method and a kit for detecting a susceptibility gene of hypertension. The invention provides a method for detecting a susceptibility gene of essential hypertension. The method comprises a step of detecting the gene type of a mitochondria fusion gene 2 (Mfn2)/ hyperplasia suppressor gene (HSG) rs2878677 locus, wherein the hypertension susceptibility of an individual of which the rs2878677 locus carries a T gene type is obviously higher than that of common people. The invention also discloses a corresponding kit for detecting the susceptibility gene of hypertension. The kit comprises a primer for amplifying the rs2878677 locus and a primer for amplifying an area comprising the rs2878677 locus in the No.2 intron of Mfn2 gene. When used for detecting the gene type of the rs2878677 locus, the method is simple and is easy to implement, is fast and efficient, and has low cost and provides a simple and direct new way for the diagnosis and treatment of hypertension.
Description
Technical field
The present invention relates to molecular biology and medical field.More specifically, relate to human mitochondrion fusion gene 2 (Mfn2 gene) single nucleotide polymorphism (single nucleotide polymorphism, SNP) site rs2878677 and with the detection of essential hypertension dependency.The invention still further relates to the method and the test kit that detect this SNP site.
Background technology
(essential hypertension EH) is a kind of multifactor, multigenic disease to essential hypertension, by the common morbific common and multiple cardiovascular disorder of environment and heredity factor, human health has been caused great influence.Along with the development of molecular medicine, kind surplus the hypertension relative gene that has been found that has at present had 150, but the pathogenesis of EH still imperfectly understands, and hypertensive early diagnosis and proactive problem still fail to solve fully.EH is the coefficient result of gene and environment, and the variation 30%-60% of blood pressure is owing to heredity.Because environmental factors can be controlled and confirm, is changeless and hypertension genetic is learned factor.Therefore, control to variable factor, as prevention, can delay and prevent hypertensive morbidity to a certain extent, but the understanding deficiency of changeless inherited genetic factors is but being had a strong impact on to a certain extent to hypertension incidence, diagnosis and treatment the hypertension Hazard Factor.Therefore the research that hypertension genetic is learned very necessary (Wang Zuoguang, Wen Shaojun, Wu Zhaosu. hypertension, tumor susceptibility gene and single nucleotide polymorphism [J]. the hypertension magazine, 2001,9:259-264).
Nearly more than two decades comes, and about the research of hypertension therapeutic concentrates on more to the control of blood pressure with to the protection of target organ, and has obtained the development of advancing by leaps and bounds.But, these means are controlling blood pressure fundamentally, at present also seldom to the research of human endogenous hypertension gene, therefore, research endogenous hypertension mechanism is one of main direction of hypertension prevention and control research from now on, has important researching value and application prospect, if by regulating endogenous hypertension mechanism treatment essential hypertension, will promote the development of China's biologic medical technology, and be the huge medical expense of the annual saving of China.
The hypertension relative gene of being found is at present summed up and is got up may be summarized to be short shr gene and hypertension gene, and Mfn2 belongs to the latter.The predecessor of Mfn2 is intelligent [the Chen GH such as grade of Chinese scholar Chen Guang, Zhang CH, Zhu YQ, et al.Expression of a novel gene related to hypertension[J] .Natl Med J China, 1997,77:823-828.] in 1997 the spontaneous hypertensive rat (SHR) of cultivation and the vascular smooth muscle cell of normal Wistar Kyoto (WKY) rat are carried out the difference demonstration, clone a new gene---and hyperplasia suppressor gene (hyperplasia suppressorgene, HSG).It includes the base pair of 4160bp, 661 amino acid of encoding altogether (NM_014874, GeneBank AccessU41803).After a series of bodies are interior, experiment in vitro is found [Chen KH, Guo XM, Dalong Ma, et al.Dysregulationof HSG triggers vascular proliferative disorders[J] .Nature Cell Biol, 2004,6,872-883.], HSG can suppress Ras-Raf albumen-Si significantly and split plain activated protein kinase genetic expression, and can activate the expression of antioncogene, check the propagation of cell cycle and inhibition various kinds of cell effectively, and this restraining effect realizes by apoptotic mode.Therefore the HSG gene is one of candidate gene of essential hypertension, after gene functional research shows, the HSG gene participates in plastosome and merges, therefore definite designation is that (mitofusin 2 for plastosome fusion gene 2, Mfn2) but at present less to the research of Mfn2 and EH, do not confirm the report of rs2878677 and EH dependency.
In sum, for the final treatment hypertension that realizes, this area presses for seeks the essential hypertension tumor susceptibility gene, and method, the test kit of exploitation detection essential hypertension tumor susceptibility gene, and relevant medicine.
Summary of the invention
The method and the detection kit that the purpose of this invention is to provide a kind of detection (comprising early diagnosis) hypertension susceptible gene.
The invention provides a kind of detection method of hypertension susceptibility gene, promptly detect the genotype in Mfn2 gene rs2878677 site, rs2878677 has the hypertensive onset risk of the genotypic individuality of T and is significantly higher than the general population.
Described rs2878677 is arranged in the intron 2 (fragment contig contig:NT_021937.19 position 8057996C/T) of Mfn2.Thymus nucleic acid (DNA) sequence numbering: the rs2878677 position is based on SEQ ID NO:1/6; Primer 1 is based on SEQ ID NO:2/6; Primer 2 is based on SEQ ID NO:3/6; Probe 1 is based on SEQ ID NO:4/6; Probe 2 is based on SEQ ID NO:5/6; Amplified production is based on SEQ ID NO:6/6.
Particularly, the method comprising the steps of: (a) genomic dna of extracting sample, and amplification obtains Mfn2 gene intron 2; (b) genotype of mononucleotide polymorphism site rs2878677 in detection step (a) product.
The primer sequence of described amplification Mfn2 gene intron 2 is shown in SEQ ID NO 2 and SEQ ID NO 3.
The genotypic probe sequence of described detection rs2878677 is shown in SEQ ID NO 4 and SEQ ID NO 5.
Technology such as the order-checking that relates in the aforesaid method, amplification, extracting genomic dna all can adopt the routine operation method of this area.
The invention provides a kind of test kit that detects hypertension susceptible gene, it contains and site rs2878677 bonded probe.
In one embodiment of the invention, with the sequence of site rs2878677 bonded probe shown in SEQ ID NO:4 and SEQID NO:5.
The mentioned reagent box can also comprise the primer that comprises the zone in rs2878677 site in the specific amplification Mfn2 gene intron 2.
Comprise the sequence of primer in zone in rs2878677 site shown in SEQ ID NO:2 and SEQ ID NO:3 in one embodiment of the invention, with in the specific amplification Mfn2 gene intron 2.
The present invention is through research for many years, proved that first Mfn2 gene mononucleotide polymorphism site rs2878677 (fragment contig contig:NT_021937.19 position 8057996C/T) and hypertension are closely related, and found its new function: Mfn2 gene mononucleotide polymorphism site rs2878677 is positioned at Mfn2, (fragment contig contig:NT_021937.19 position 8057996C/T) genotypic change will cause hypertensive onset risk to raise in the intron 2, wherein the association study result shows, there is significant difference (p＜0.05) in the distribution of Mfn2 gene rs2878677C → T in case and control group, and this SNP polymorphism can change the transcription factor binding site point.Finished the present invention on this basis.
The invention provides a kind of method that the hypertension susceptibility of individuality is diagnosed, it comprises step: detect the genotype in this individual Mfn2 gene rs2878677 site, judge that with this this individuality suffers from hypertensive onset risk and whether be higher than the general population.
In a preference, described difference is the single nucleotide polymorphism that is selected from rs2878677.Rs2878677 is positioned at Mfn2, in the intron 2 (fragment contig contig:NT_021937.19 position 8057996C/T).Wherein, thymus nucleic acid (DNA) sequence numbering: the rs2878677 position is based on SEQ ID NO:1/6.
The invention provides the method whether a kind of test sample exists the single nucleotide polymorphism of Mfn2 gene, comprise step:
(a) with the genomic dna of Mfn2 gene intron 2 primer amplified samples, obtain amplified production; With
(b) genotype of mononucleotide polymorphism site rs2878677 in the detection amplified production.
The detailed sequence of Mfn2 gene can be the nucleotide sequence (can referring to network address http://www.ncbi.nlm.nih.gov/) of rs2878677 referring to accession number.
The inventor checks order to (fragment contig contig:NT_021937.19 position 8057996C/T) zone in the intron in the Mfn2 gene 2.
The polymorphism in Mfn2 gene rs2878677 site can be directly used in hypertensive personalized treatment.When using the polymorphism in Mfn2 gene rs2878677 of the present invention site, also can use the hypertensive medicament of other treatment simultaneously.
The present invention also provides a kind of pharmaceutical composition, and it contains Mfn2 albumen of the present invention safely and effectively and pharmaceutically acceptable carrier or vehicle.This class carrier comprises (but being not limited to): salt solution, damping fluid, glucose, water, glycerine, ethanol and combination thereof.Pharmaceutical preparation should be complementary with administering mode.Pharmaceutical composition of the present invention can be made into the injection form, for example is prepared by ordinary method with the physiological saline or the aqueous solution that contains glucose and other assistant agents.Pharmaceutical composition such as tablet and capsule can be prepared by ordinary method.Pharmaceutical composition such as injection, solution, tablet and capsule are made under aseptic condition.The dosage of activeconstituents is the treatment significant quantity, for example every day 0.1 microgram/kg body weight-Yue 10 mg/kg body weight.In addition, polypeptide of the present invention also can use with the other treatment agent.
When making pharmaceutical composition, be that the Mfn2 albumen of safe and effective amount or its antagonist, agonist are applied to general Mammals, wherein this safe and effective dosage is usually at least about 0.1 microgram/kg body weight, and in most of the cases be no more than about 10 mg/kg body weight, preferably this dosage is about 0.1 microgram/kg body weight-Yue 100 mg/kg body weight.Certainly, concrete dosage also should be considered factors such as route of administration, patient health situation, and these all are within the skilled practitioners skill.
The genotype that detects the rs2878677 of Mfn2 gene also can be used for diagnosing hypertension.Detection can be at genomic dna, also can be at the amplified fragments of Mfn2 gene.The genotype of the rs2878677 of Mfn2 gene can detect sudden change with existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization.
The invention provides a kind of method that detects the essential hypertension susceptible gene, it comprises the genotype in the rs2878677 site of detection line plastochondria fusion gene 2 (Mfn2), rs2878677 has the genotypic individuality of T, and hypertensive susceptibility is significantly higher than the general population.The invention also discloses the relevant detection test kit, this test kit contains the primer in amplification rs2878677 site, can also comprise the primer in No. 2 intron zone of amplification Mfn2 gene.Utilize the present invention to detect the genotype in rs2878677 site, method is simple, and is rapidly and efficiently with low cost, for hypertensive diagnosis and treatment provide a simple and direct new way.
Description of drawings
Fig. 1 is the detected result of MFn2 gene rs2878677 loci gene type.
Fig. 2 is the sequencing result sectional drawing.Wherein, Mfn2 rs2878677 is positioned at Mfn2, the genotypic sequencing result of a kind of SNP of (fragment contig contig:NT_021937.19 position 8057996C/T) in the intron 2.
Embodiment
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning; Condition described in the laboratory manual (New York:Cold Spring Harbor Laboratory Press, 1989), or the condition of advising according to manufacturer.
Embodiment 1 fluorescent PCR detects
One, experiment material
The 7900HT quantitative real time PCR Instrument is available from American AB I company, and pcr reaction solution (TaqMan EXPress Master Mix) is synthetic by u.s.a. applied biosystem company (ABI) customization.
Two, primer and probe design and synthetic:
Partial sequence with MFn2 gene intron 2 is a template, uses Primer ExpressTM 2.0 software analysis TaqMan primer and probe site, and synthetic by u.s.a. applied biosystem company (ABI) customization.
Detect and use primer:
MFn2 gene rs2878677 upstream primer sequence: 5 '-TTCTACTTTCTGTCCCTATGAATTTGA-3 ' (SEQ ID NO 2)
MFn2 gene rs2878677 downstream primer sequence: 5 '-ACAAATACTGTATGATTCCACTTACGT-3 ' (SEQ ID NO 3) fluorescent probe:
MFn2 gene rs2878677 fluorescent probe 1:5 '-VIC-attctagaCgtctcacgt-TAMRA-3 ' (SEQ ID NO 4)
MFn2 gene rs2878677 fluorescent probe 2:5 '-FAM-ctattctagaTgtctcacgt-TAMRA-3 ' (SEQ ID NO 5)
Three, pattern detection:
Experiment detects 917 routine hypertension cases and 460 routine normal control crowds altogether, and every example is collected the about 2ml of blood sample sample, and with phenol/chloroform drawer genomic dna, the extracting result detects with micro-ultraviolet spectrophotometer (INFINIGEN company).
Carry out the fluorescent PCR amplification by following system, at last with SDS 2.3 scanning and cluster analyses.
| 384 orifice plates (ul) | |
| TaqMan?EXPress?Master?Mix(2X) | ?2.5 |
| 20X?working?stock?of?SNP?Genotyping?Assay | ?0.25 |
| GDNA (about 3ng/ul) | ?2.25 |
| The reaction cumulative volume | ?5 |
Four, type detected result:
The detected result of genome DNA extraction:
The genomic dna coincidence detection of all samples requires (260/280＞1.8, concentration＞10ng/ul, the detected result of No. 1177, sample as shown in Figure 1).
The detected result of MFn2 gene rs2878677 loci gene type
Embodiment 2
Detect the rs2878677 site of essential hypertension tumor susceptibility gene MFn2 gene with sequencing.Selecting each 10 example of above-mentioned hypertension case-control group sample checks order and judges the genotype of rs2878677.
One, experimental technique
The PCR sequencing primer still adopts above-mentioned fluorescent PCR primer, the directly order-checking of the purified back of the product of amplification.The instrument of order-checking is the 3130xl genetic analyzer of ABI company, analyzes with sequence analysis 5.2 analysis software, and the result also can check with chromas.
Two, experimental result
Finally, the gene type assay result of the sequencing result of 20 examples and 7900 fluorescent PCRs is in full accord.
Three, the association analysis of MFn2 gene rs2878677 genotype and hypertension susceptible
The relatively employing RxC χ that MFn2 gene rs2878677 distributes in hypertensive patient and contrast
2Check. carry out statistical study with SPSS software, detected result and SPSS software analysis result are as shown in the table:
All documents of mentioning in the present invention are all quoted in this application and are done reference, are just quoted as a reference separately as each piece document.Should be understood that in addition read of the present invention above-mentioned tell about content after, those skilled in the art can make various changes or modification to the present invention, these forms fall within the application's appended claims institute restricted portion equally.
Claims (9)
1. the detection method of a hypertension susceptibility gene is characterized in that, detects the genotype in Mfn2 gene rs2878677 site, and rs2878677 has the hypertensive onset risk of the genotypic individuality of T and is significantly higher than the general population.
2. detection method as claimed in claim 1 is characterized in that the rs2878677 site is positioned at Mfn2 gene intron 2.
3. detection method as claimed in claim 1 is characterized in that the method comprising the steps of:
(a) genomic dna of extracting sample, amplification obtains to comprise in the Mfn2 gene intron 2 zone in rs2878677 site;
(b) genotype of mononucleotide polymorphism site rs2878677 in detection step (a) product.
4. detection method as claimed in claim 3 is characterized in that, the primer sequence in zone that comprises the rs2878677 site in the amplification Mfn2 gene intron 2 is shown in SEQ ID NO 2 and SEQ ID NO 3.
5. detection method as claimed in claim 3 is characterized in that, the genotypic probe sequence that detects rs2878677 is shown in SEQ ID NO 4 and SEQ ID NO 5.
6. a test kit that detects hypertension susceptible gene is characterized in that, it contains and site rs2878677 bonded probe.
7. test kit as claimed in claim 6 is characterized in that, with the sequence of site rs2878677 bonded probe shown in SEQ ID NO 4 and SEQ ID NO 5.
8. test kit as claimed in claim 6 is characterized in that, it also comprises the primer that comprises the zone in rs2878677 site in the specific amplification Mfn2 gene intron 2.
9. test kit as claimed in claim 8 is characterized in that, the sequence of primer in zone that comprises the rs2878677 site in the specific amplification Mfn2 gene intron 2 is shown in SEQ ID NO 2 and SEQ ID NO 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010171050 CN101979657B (en) | 2010-05-11 | 2010-05-11 | Method and kit for detecting rs2878677 locus of susceptibility gene of hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010171050 CN101979657B (en) | 2010-05-11 | 2010-05-11 | Method and kit for detecting rs2878677 locus of susceptibility gene of hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101979657A true CN101979657A (en) | 2011-02-23 |
| CN101979657B CN101979657B (en) | 2013-02-27 |
Family
ID=43600195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010171050 Expired - Fee Related CN101979657B (en) | 2010-05-11 | 2010-05-11 | Method and kit for detecting rs2878677 locus of susceptibility gene of hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101979657B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104099329A (en) * | 2013-04-02 | 2014-10-15 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility related gene locus and detection method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1902327A (en) * | 2004-01-07 | 2007-01-24 | 中国医学科学院阜外心血管病医院 | Primary hypertension relative gene and its detecting method and usage |
| US20070092888A1 (en) * | 2003-09-23 | 2007-04-26 | Cornelius Diamond | Diagnostic markers of hypertension and methods of use thereof |
| CN101608219A (en) * | 2008-06-20 | 2009-12-23 | 上海主健生物工程有限公司 | Hypertension genetic test kit |
-
2010
- 2010-05-11 CN CN 201010171050 patent/CN101979657B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070092888A1 (en) * | 2003-09-23 | 2007-04-26 | Cornelius Diamond | Diagnostic markers of hypertension and methods of use thereof |
| CN1902327A (en) * | 2004-01-07 | 2007-01-24 | 中国医学科学院阜外心血管病医院 | Primary hypertension relative gene and its detecting method and usage |
| CN101608219A (en) * | 2008-06-20 | 2009-12-23 | 上海主健生物工程有限公司 | Hypertension genetic test kit |
Non-Patent Citations (3)
| Title |
|---|
| 《Chinese Journal of Hypertension》 20010731 王佐广 高血压、易感基因与单核苷酸多态性 259-264 第9卷, 第3期 * |
| 《Hypertension》 19940731 Alain Bonnardeaux,et al Angiotensin II Type 1 Receptor Gene Polymorphisms in Human Essential Hypertension 63-69 第24卷, 第1期 * |
| 《J Hum Genet》 20071231 Norihisa Osawa,et al Combinational effect of genes for the renin-angiotensin system in conferring susceptibility to diabetic nephropathy 143-151 第52卷, * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104099329A (en) * | 2013-04-02 | 2014-10-15 | 首都医科大学附属北京安贞医院 | Hypertension susceptibility related gene locus and detection method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101979657B (en) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101892302B (en) | Use and detection kit of locus rs2336384 of susceptibility gene of hypertension | |
| CN101892311B (en) | Detection method and kit of single nucleotide polymorphism locus rs7550536 of susceptibility gene of hypertension | |
| CN101892305B (en) | Method for detecting rs2295281 locus of hypertension susceptibility gene and detection kit | |
| CN102586408B (en) | The detection method of hypertension susceptible gene Mfn2 mononucleotide polymorphism site rs3820189 and detection kit | |
| Ryu et al. | − 759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment | |
| Pawlik et al. | Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone | |
| dos Santos et al. | The− 374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes | |
| EP3207136A1 (en) | Methods and compositions for treating a subject with a smad7 antisense oligonucleotide | |
| KR20120093297A (en) | Methods and systems for pharmacogenomic treatment of cardiovascular conditions | |
| CN102808030B (en) | Application of single nucleotide polymorphism rs3888188 in detection of tuberculosis susceptibility | |
| CN101886125B (en) | Method for detecting mononucleotide polymorphism locus rs2236058 of hypertension susceptibility genes and detection kit | |
| CN101892297B (en) | Detection method of single nucleotide polymorphism sites of hypertension susceptibility gene and kit thereof | |
| CN101886121B (en) | Method for detecting locus rs873457 of hypertension susceptibility genes and detection kit | |
| CN101886129B (en) | Method for detecting mononucleotide polymorphism locus rs388915 of hypertension susceptibility genes AGTR 1 and detection kit | |
| CN101892298B (en) | Method for detecting mononucleotide polymorphism rs2236055 locus of hypertension susceptibility gene and kit thereof | |
| CN101892296B (en) | Method for detecting hypertension susceptible gene and detection kit | |
| CN101979657B (en) | Method and kit for detecting rs2878677 locus of susceptibility gene of hypertension | |
| CN101892303B (en) | Method for detecting rs4846085 locus of hypertension susceptibility gene and detection kit thereof | |
| CN101892301B (en) | Method for detecting hypertension susceptibility gene and detection kit | |
| Ishiguro et al. | No association between C-45T polymorphism in the Sp1 binding site of the promoter region of the cholecystokinin gene and alcoholism | |
| CN101805784B (en) | Single nucleotide polymorphism of human WNK4 genes and application thereof | |
| CN104419759A (en) | Detection method and detection kit for single nucleotide polymorphism site rs7975232 of lung cancer susceptibility gene | |
| CN104099329A (en) | Hypertension susceptibility related gene locus and detection method thereof | |
| CN102732602A (en) | Method for detecting gene rs2255390 site of hypertension susceptible gene WNK1 and detection kit thereof | |
| CN104450688A (en) | Hypertension susceptibility relevant gene variation locus and detecting method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130227 Termination date: 20170511 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |